Expert consensus on the diagnosis and treatment in advanced non-small cell lung cancer with BRAF mutation in China.
10.3760/cma.j.cn112152-20230117-00030
- Collective Name:Lung Cancer Professional Committee of Chinese Anti-Cancer Association
- Publication Type:Journal Article
- Keywords:
BRAF;
BRAF V600;
BRAF inhibitors;
Lung neoplasms;
MAPK inhibitors;
Non-small cell lung cancer
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/genetics*;
Lung Neoplasms/genetics*;
Proto-Oncogene Proteins B-raf/genetics*;
Consensus;
Mutation
- From:
Chinese Journal of Oncology
2023;45(4):279-290
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is the malignant tumor with the highest incidence and mortality rate in China, among which non-small cell lung cancer (NSCLC) accounts for about 85%. BRAF mutation occurs about 1.5% to 5.5% in NSCLC patients, while BRAF V600 accounts for about 30% to 50% of all BRAF mutations. The overall prognosis of patients with BRAF-mutation is poor. At present, there are many clinical trials on BRAF-mutation NSCLC and new drugs constantly emerging. However, there is no standardized consensus on the diagnosis and treatment of BRAF-mutation NSCLC in China. The expert group of the Lung Cancer Professional Committee of the Chinese Anti-Cancer Association formulated this consensus by integrating foreign and domestic BRAF-mutation-related guidelines, consensus, and existing clinical trials, and combining with Chinese experts' clinical experience in the diagnosis and treatment of BRAF-mutation NSCLC. This consensus provides systematic recommendations for the clinical diagnosis and treatment process, rational drug choice, and adverse events management of BRAF-mutation NSCLC, aiming to provide reference for the standard of diagnosis and treatment of BRAF-mutation NSCLC.
